Who is sponsoring NCT04599777?

NCT04599777 is sponsored by Second Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT04599777?

Interventions in NCT04599777: TACE combined with sorafenib and tislelizumab.

What condition does NCT04599777 study?

NCT04599777 studies Hepatocellular Carcinoma Non-resectable.

Is NCT04599777 still recruiting?

NCT04599777 is currently completed. Last updated 13 October 2022.

Last reviewed 2022-10-13 · How we verify

NCT04599777

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Completed Phase 2 Last updated 13 October 2022

What this trial tests

Phase 2 trial testing TACE combined with sorafenib and tislelizumab in Hepatocellular Carcinoma Non-resectable in 30 participants. Completed in 11 October 2022.

Timeline

1 October 2020

Primary endpoint
11 October 2022

11 October 2022

Quick facts

Lead sponsor	Second Affiliated Hospital of Guangzhou Medical University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 October 2020
Primary completion	11 October 2022
Estimated completion	11 October 2022
Sites	2 locations across China

Drugs / interventions tested

TACE combined with sorafenib and tislelizumab — full drug profile →

Conditions studied

Hepatocellular Carcinoma Non-resectable — all drugs for Hepatocellular Carcinoma Non-resectable →

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with Hepatocellular Carcinoma Non-resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, et al · · 2022 · cited 23× · PMID 35655707 · DOI 10.1080/2162402x.2022.2077898
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B, Tan DJH, Lim WH, Wong JSL, et al · · 2023 · cited 4× · PMID 37284696 · DOI 10.1080/2162402x.2023.2214478
Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma.
Han F, Wang XH, Xu CZ. · · 2024 · cited 2× · PMID 39072161 · DOI 10.4251/wjgo.v16.i7.3308
Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study.
Liang L, Zhou J, Huang J, Guo Y, et al · · 2025 · cited 1× · PMID 41179951 · DOI 10.2147/itt.s543741

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma Non-resectable

Currently open trials in the same condition.

NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting
NCT06561399 — Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003) · recruiting
NCT06492395 — Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT · Phase 3 · recruiting
NCT06397235 — DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC · Phase 2 · recruiting

Other Second Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT06966830 — Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus · not yet recruiting
NCT06936683 — Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） · not yet recruiting
NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting
NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04599777 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Guangzhou Medical University
Last refreshed: 13 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04599777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing